Is Neuraxis going out of business?

Neuraxis, INC (NRXS) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

Neuraxis, INC (NRXS) scores 26 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Interest coverage: -73.7x

Five questions, kept separate

Survival - Fragile

13-18 mo of estimated runway from 2026-06-30, based on $8.3M of cash and short-term investments against $6.5M of annual burn. A disclosed filing event caps this reading; Event Risk carries the detail.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Balanced

5.9% net-cash backing support a balanced pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. It appears across 4 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Interest coverage: -73.7x
• Filing event risk: Going-Concern Warning (-8 pts)
• Revenue CAGR (3Y): 22.78%
• Shares dilution YoY: 45.97% (YoY)
• Debt / Equity: No financial debt (debt-free)
• Return on Assets: -78.04%
• Revenue growth YoY: 115.72% (YoY) - Early-Stage Surge (low base)
• FCF margin: -181.10% (Inv. Mode)
• Asset Growth Velocity: 41.03% YoY (Scaling infra)
• Cash Burn Deceleration: -53.59% QoQ improvement (Worsening)
• Working Capital Efficiency: 1002.34x (Well-funded)
• Revenue Quality: Quality concerns (DSO +30d, Rev +116%)

Read from filings through 2026-08-19.

Price as of 2026-09-07.